Ann Li Lee
Director/Board Member chez JW (CAYMAN) THERAPEUTICS CO. LTD
Profil
Ann Li Lee is currently an Independent Non-Executive Director at JW (Cayman) Therapeutics Co. Ltd.
since 2020 and a Senior Vice President at Celgene Corp.
since 2018.
Previously, she held the position of Senior Vice President at Genentech, Inc. and Executive Vice President-Technical Operations at Juno Therapeutics, Inc. Dr. Lee obtained a doctorate degree from Yale University in 1990 and an undergraduate degree from Cornell University in 1983.
Postes actifs de Ann Li Lee
| Sociétés | Poste | Début |
|---|---|---|
| JW (CAYMAN) THERAPEUTICS CO. LTD | Director/Board Member | 22/05/2020 |
| CELGENE | Corporate Officer/Principal | 01/03/2018 |
Anciens postes connus de Ann Li Lee
| Sociétés | Poste | Fin |
|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | - |
Formation de Ann Li Lee
| Yale University | Doctorate Degree |
| Cornell University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| JW (CAYMAN) THERAPEUTICS CO. LTD | Health Technology |
| Entreprise privées | 3 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
